Clinical observation of Remimazole tosylate for general anesthesia with Laryngeal Mask Airway in middle-aged and elderly patients undergoing urological surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039604

Enrollment

Unknown

Registered

2020-11-03

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological short-term minimally invasive surgery

Interventions

Experiment Group 1:remimazolam tosylate 0.2mg/kg induction+remimazolam tosylate 1mg/kg/h maintain

Experiment Group 2:remimazolam tosylate 0.3mg/kg induction+remimazolam tosylate 1mg/kg/h maintain

Experiment Group 3:remimazolam tosylate 0.4mg/kg induction+remimazolam tosylate 1mg/kg/h maintain

Control Group:propofol 2.0-2.5mg/kg induction+propofol 4-10mg/kg maintain

Eligibility

Sex/Gender

All

Age

45 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. ASA I-II patients; 2. Patients aged between 45 and 69 years old; 3. The patients who underwent the short and minimally invasive surgery in urology department and completed the routine preoperative examination.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to remimazolam tosylate and patients allergic to other drugs used in this experiment; 2. Patients who have used narcotic sedatives, analgesics or non-steroidal anti-inflammatory drugs for a long time; 3. Opioid dependent or opioid tolerant patients; 4. Despite the use of vasoactive drugs, there are still patients with systemic hypotension; 5. Patients with bradycardia and heart rate less than 55 beats/min before surgery; 6. Patients with high atrioventricular block without a pacemaker; 7. Patients with severe adverse reactions or accidental anesthesia during surgery; 8. Patients with craniocerebral injury and intracranial hypertension; 9. Patients with severe heart, lung, liver, and kidney function abnormalities; 10. Patients with previous allergic diseases; 11. Patients with previous mental illness;

Design outcomes

Primary

Measure	Time frame
Circulatroy system change;MOAA/S socre;time required to remove the throat mask;time required to leave operating room;	—

Secondary

Measure	Time frame
the optimal induction dose of remimazolam tosylate;	—

Countries

China

Contacts

Public ContactHe Mingyan

Hu'nan Provincial People's Hospital

274900424@qq.com+86 18684806726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026